GlassScriptPhysician profile
Ryan J Clarke
NPI 1083058937
$8,955.65
in general payments reported to CMS, 2019-2025
47 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $1,362 · 2021: $1,540 · 2022: $1,573 · 2023: $1,220 · 2024: $1,037 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,395.38 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $866.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $672.74 | 2019-2025 | |
| Abbvie INC. | $615.14 | 2019-2025 | Ubrelvy, Vraylar, Viberzi |
| Glaxosmithkline, LLC. | $596.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $488.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.34 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $378.20 | 2019-2025 | Otezla, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $272.90 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $251.77 | 2019-2024 | Trintellix, Glassia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $243.67 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $241.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $227.69 | 2019-2022 | |
| Exact Sciences Corporation | $227.12 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $226.38 | 2019-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.